Dear Freddie
Private Equity Investor at Monograph Capital Advisors (UK) LLP
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Tim Funnell | M | - |
Ascend Gene & Cell Therapies Ltd.
 Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021.
Monograph Capital Advisors (UK) LLP
 Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
| Fred Cohen | M | 67 |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
| Timothy Funnell | M | 38 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 3 years |
| Michael LaGatta | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 1 years |
| Charles Conn | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
| Travis Murdoch | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
| Michael Charles Beecham | M | 36 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
| Stephanie Fox | F | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 1 years |
| Nishat Miah | F | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
| Luke Pike | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 2 years |
| Jaideep Dudani | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
| Eric Norio Shiozaki | M | 47 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
| Balaji Muralidhar | M | 45 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
| Sarah Crabtree | F | - |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 3 years |
| Annabel Clark | F | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 6 years |
| Fred Cohen | M | 68 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | - |
| Fiona Langton-Smith | F | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 3 years |
| Gonzalo Garcia | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 4 years |
| Michael Kyriakides | M | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 6 years |
| Magdalena Jonikas | F | - |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | 6 years |
| Bonnie van Wilgenburg | M | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 3 years |
| Andrey Kozlov | M | 48 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
| Mike Stella | M | - |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bryan Geoffrey Morton | M | 67 |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | - |
| George Ribaroff | M | - |
The University of Edinburgh
| 6 years |
| Sebastian Anastassiou | M | - |
The University of Edinburgh
| 4 years |
| Leslie Andrew | M | - |
The University of Edinburgh
| 4 years |
| Rui Zu | F | 33 |
The University of Edinburgh
| 1 years |
| Linnea Boestad | F | - |
The University of Edinburgh
| 4 years |
| Ya Gao | F | 30 |
The University of Edinburgh
| 2 years |
| Kate Clarfelt | F | - |
The University of Edinburgh
| 4 years |
| Julia Lenon | F | - |
The University of Edinburgh
| 4 years |
| Shosh Shetty | M | - |
The University of Edinburgh
| 4 years |
| Andrew Muirhead | M | - |
The University of Edinburgh
| 4 years |
| Louis Origny | M | - |
The University of Edinburgh
| 4 years |
| Stefan Zlatev | M | - |
The University of Edinburgh
| 4 years |
| Edward Leeming | M | - |
The University of Edinburgh
| 4 years |
| Nadia Miranty Verdiana | F | 33 |
The University of Edinburgh
| 3 years |
| Victoria Ordsmith | F | - |
The University of Edinburgh
| 1 years |
| Harry Howarth | M | - |
The University of Edinburgh
| 4 years |
| Dan Lukpanov | M | - |
The University of Edinburgh
| 1 years |
| Omar El-Labban | M | - |
The University of Edinburgh
| 2 years |
| Omar Omar | M | - |
The University of Edinburgh
| 1 years |
| Lucinda Laing | F | - |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | 2 years |
| Andrew Paul May | M | 51 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | - |
| Max Haddock | M | - |
The University of Edinburgh
| 4 years |
| Thomas Tynan | M | - |
The University of Edinburgh
| 4 years |
| Nic Carter | M | - |
The University of Edinburgh
| 1 years |
| Grace Smalley | F | - |
The University of Edinburgh
| 4 years |
| Akua Gilfillian | F | - |
The University of Edinburgh
| 3 years |
| Dominic Jacobson | M | - |
The University of Edinburgh
| 4 years |
| Christopher Leonard | M | - |
The University of Edinburgh
| 1 years |
| Tom Jones | M | - |
The University of Edinburgh
| 4 years |
| Natalia Winkler | F | - |
The University of Edinburgh
| 1 years |
| Edward Thomason | M | - |
The University of Edinburgh
| 4 years |
| Charlie Kickham | M | - |
The University of Edinburgh
| 4 years |
| Gracie Lynne | F | - |
The University of Edinburgh
| 1 years |
| Bindesh Savjani | M | - |
The University of Edinburgh
| 6 years |
| Sam Taylor | M | - |
The University of Edinburgh
| 4 years |
| Ellen Logan | F | - |
The University of Edinburgh
| 4 years |
| Jos North | M | - |
The University of Edinburgh
| 4 years |
| Benzahia Alison | F | - |
The University of Edinburgh
| 5 years |
| Molly Greenen | F | - |
The University of Edinburgh
| 4 years |
| Nick Morris | M | - |
The University of Edinburgh
| 4 years |
| Shrenik Kenia | M | - |
The University of Edinburgh
| 1 years |
| Matt Pierce | M | - |
The University of Edinburgh
| 4 years |
| Michael Bottjer | M | - |
The University of Edinburgh
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 67 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dear Freddie
- Personal Network
